Lung Cancer Update for Nurses, Issue 1

You are here: Home: LCU Nurses 1 | 2008: CNE Information

STATEMENT OF NEED/TARGET AUDIENCE

Lung cancer is the leading cause of cancer mortality in the United States in both men and women. Chemotherapy, surgery and radiation therapy have had a modest effect on patient outcomes. However, recent improvements have been seen in time to progression and survival in lung cancer clinical trials. Research findings and ongoing clinical trials lead to the continuous emergence of new drugs and therapies and changes in the indications for existing treatments. To offer their patients the best care possible, oncology nurses need to be aware of ongoing research and changes in cancer care so as to include the widening array of therapeutic options for cancer patients in their everyday disease management decisions. To assist with meeting this need, Lung Cancer Update for Nurses provides an overview of the latest research developments in lung cancer and the opinions of patients, oncology nurses and clinical investigators with experience and expertise in the field.

PURPOSE STATEMENT

To present the most current research developments in lung cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of lung cancer.

EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF LUNG CANCER UPDATE FOR NURSES

Critically evaluate emerging clinical trial data on targeted molecular therapies and new formulations of commonly used chemotherapies, and integrate these agents into the treatment for appropriate patients with non-small cell lung cancer (NSCLC).
Identify the subgroup of patients with epidermal growth factor receptor-mutated NSCLC, and incorporate tyrosine kinase inhibitors, with consideration of their efficacy and toxicity profiles, into the treatment for appropriate patients.
Counsel appropriate patients on the effects of agents targeting vascular endothelial growth factor in the treatment of NSCLC, including benefits and risks, and integrate these agents, as indicated, into treatment regimens.
Identify treatment-related toxicities, provide patient education on these side effects and develop management strategies to minimize or alleviate symptoms.
Discuss the psychosocial and emotional needs of caregivers, patients and their loved ones associated with the diagnosis and treatment of lung cancer.

ACCREDITATION STATEMENTS

This educational activity for 2.5 contact hours is provided by Research To Practice during the period of May 2008 through May 2009.

Research To Practice is an approved provider of continuing nursing education by the New Jersey State Nurses Association, Provider Number P215-01/07-10. NJSNA is accredited by the ANCC Commission on Accreditation. Provider Approval is valid through January 31, 2010.

HOW TO USE THIS CNE ACTIVITY

This is an audio CNE activity. This website contains a continuing nursing education Post-test and Evaluation Form, and links to relevant full-text articles and abstracts. There are no fees for participating and receiving CNE credit for this activity. To receive credit during the period of May 2008 through May 2009, participants should read the learning objectives and faculty disclosures, listen to the audio program and complete the Post-test and Evaluation Form. Certificates may be printed online or mailed to participants.

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP and Genentech BioOncology/OSI Pharmaceuticals Inc.